Behavioral Neurology

Featured Article
This roundup discusses a variety of new findings presented at the 33rd European College of Neuropsychopharmacology Congress (Virtual).
By evaluating the cognition and depressive symptoms of more than 10,900 participants in the Add Health study, researchers determined the association between these symptoms in young adulthood and contact sport participation in adolescence.
Concomitant anxiety is common among patients with restless legs syndrome (RLS). Based on the AAN’s guideline on RLS treatment in adults, which medication is recommended for patients with RLS and concomitant anxiety?
Dr Abbey Hughes from Johns Hopkins University School of Medicine talks about her research on anxiety screening in patients with multiple sclerosis.
New research suggests that as persons with MS age, their quality of life and severity of depression change.
New data on nearly 71,000 patients with Alzheimer disease point toward a potential association between Alzheimer risk and the use of commonly prescribed treatments for anxiety, insomnia, and related conditions.
For many patients with major depressive disorder, how does the course of their depression change over time?
In 2006, the US Food and Drug Administration issued an advisory that warned of the risk for serotonin syndrome with concomitant use of triptans and certain antidepressants. In a recent study, researchers aimed to assess this risk further.
Previous research has suggested that anxiety, depression, and other neuropsychiatric symptoms could predict the progression of preclinical AD, which can occur more than a decade before cognitive impairment begins.